Last updated: May 1, 2024
Sponsor: Verily Life Sciences LLC
Overall Status: Completed
Phase
N/A
Condition
Insomnia
Sleep Apnea Syndromes
Treatment
Actiwatch
Study Watch
Clinical Study ID
NCT05276362
103845
Ages 18-80 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participant is ≥ 18 and ≤ 80 years old
- Participant understands the study requirements and is able and willing to providewritten informed consent
- Participant is without significant limitation in ability to participate in the study,in the opinion of the investigator
- Participant belongs to one of the following participant groups as determined byscreening questionnaires:
- Typical sleepers (i.e., STOP-Bang score of 0-2 or OSA50 < 5, Insomnia SeverityIndex (ISI) < 8, and Epworth Sleepiness Scale (ESS) < 10), and no evidences ofsleep-disordered breathing at the PSG evaluation
- Insomnia sleepers (i.e., ISI > 10 and PSG AHI < 5)
- Sleep apnea sleepers (i.e., STOP-Bang score of 3-8 or OSA50 ≥ 5) or moderate tosevere obstructive sleep apnea (PSG AHI ≥5))
- Participant has agreed to abstain from caffeine, nicotine, alcohol, and cannabisproducts for 8 hours prior to the In-Lab Screening Visit and until the visit iscompleted
- Exception - unless the participant use of product has approval from the PrincipalInvestigator
- Participant has agreed to abstain from OTC or PRN medications that are not regularlyused on a daily basis and may affect sleep/wakefulness for 24 hours prior to theIn-Lab Overnight Visit and during the study visit
- Exception - unless the participant uses OTC or PRN medication on a routine basisand has approval from the Principal Investigator
Exclusion
Exclusion Criteria: Conditions based on self-report of having been told by a doctor of aformal diagnosis
- Presence of any of the following diagnosed sleep, medical, or psychiatric disorders:
- Sleep
- Narcolepsy
- Restless leg syndrome
- Circadian rhythm sleep disorder
- Periodic Limb Movement Disorder
- REM Sleep behavior disorder
- Medical
- Epilepsy or other seizure disorder
- Renal failure or chronic kidney disease
- Acute or chronic infection that may interfere with the study
- Movement neurological disorder that impairs movement or autonomic stability (e.g. Parkinson's disease, Huntington's disease)
- Cardiopulmonary diseases (e.g. heart failure, chronic obstructive pulmonarydisease, ventilatory disorders)
- Persistent arrhythmias and dysrhythmias
- Severe neuromuscular disease (e.g. Amyotrophic lateral sclerosis [ALS])
- Psychiatric
- Severe significant mood disorder (e.g. depression, bipolar disorder)
- Substance use disorder
- Participant uses supplemental oxygen during the day or night
- Participant is unwilling to cease use of CPAP or oral appliance for sleep-disorderedbreathing during the In-Lab Overnight Visit; or cessation is deemed to be ofsubstantial risk in the opinion of the Principal Investigator
- Women who are pregnant, lactating, or breastfeeding
- Participant takes prescription stimulants, sedatives, opioids, alpha blockers, shortacting nitrates, or any other medication that, in the opinion of the PrincipalInvestigator and study team, impacts their sleep behavior
- Use of any sleep medications (over-the-counter or prescription) in the previous 24hours for Typical Sleepers
- Participant has a cardiac pacemaker, implantable defibrillator, medical pump, or otherimplantable medical electronic device
- Participant has Shift Work Sleep Disorder (SWSD) or is a night-shift worker
- Participant has traveled >3 time zone within two weeks prior to study
- Participant is not fluent at reading and speaking English
- Participant is deemed not to be a candidate for the study, in the opinion of thePrincipal Investigator
- Known severe allergy to nickel or metal jewelry
- Open injury or rash where the study device or comparator will be worn
- Known severe allergy to polyester, nylon, or spandex material
- Enrolled participants who meet exclusion criteria after PSG, upon confirmation withthe principal investigator and study team, will be discontinued and excluded fromprimary analyses.
Study Design
Total Participants: 90
Treatment Group(s): 2
Primary Treatment: Actiwatch
Phase:
Study Start date:
March 04, 2022
Estimated Completion Date:
September 20, 2023
Connect with a study center
SRI International
Menlo Park, California 94025
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.